Key facts
- This page summarizes Nima Farzan's Form 3 filing for Latigo Biotherapeutics, Inc. (LTGO).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 06 Aug 2026, 20:31.
Nima Farzan - 06 Aug 2026 Form 3 Insider Report for Latigo Biotherapeutics, Inc. (LTGO)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- LTGO
- Reported as of
- 06 Aug 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Aug 2026, 20:31:24 UTC
- Prior SEC filing
- 08 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sabrina Nieder, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nima Farzan filed Form 3 for Latigo Biotherapeutics, Inc. (LTGO) on 06 Aug 2026.
Change
- Previous filing in this sequence was filed on 08 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001808296
Primary reporting owner
Farzan Nima
- Relationship
- President and CEO, Director
- Address
- C/O LATIGO BIOTHERAPEUTICS, INC., 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS
- Signature
- /s/ Sabrina Nieder, Attorney-in-Fact
- Signature date
- 06 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LTGO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 114,453
- Date
- 06 Aug 2026
- Ownership
- By Farzan 2026 Descendants' Trust f/b/o ZAF
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LTGO
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,703,288
- Exercise price
- $2.19
- Footnotes
- F2
LTGO
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 676,468
- Exercise price
- $5.53
- Footnotes
- F3
LTGO
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 136,070
- Exercise price
- $5.53
- Footnotes
- F3
LTGO
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 272,140
- Exercise price
- $5.53
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The Reporting Person is trustee of Farzan 2026 Descendants' Trust f/b/o ZAF
Footnote F2
One-fourth of the total shares subject to this option shall vest one year after July 15, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Footnote F3
One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.